Log in to your Inderes Free account to see all free content on this page.

ALK-Abelló

227.40 DKK

+0.26 %

Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+0.26 %

0.00 %

+8.49 %

+25.64 %

+42.93 %

+40.98 %

+138.74 %

+97.40 %

+559.13 %

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Market cap

50.67B DKK

Turnover

27.23M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All

Press releases

ShowingAll content types

Press release5 hours ago

ALK – Financial calendar for the 2026 financial year

Regulatory press release12/19/2025, 9:46 PM

Major shareholder announcement

Regulatory press release12/1/2025, 2:35 PM

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/12/2025, 4:22 PM

Nine-month interim report (Q3) 2025 (unaudited)

Regulatory press release11/12/2025, 4:16 PM

ALK upgrades its full-year outlook

Press release11/6/2025, 4:01 PM

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

Regulatory press release9/17/2025, 7:44 AM

ALK and GenSci partner to expand the AIT market in China

Press release9/8/2025, 12:21 PM

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

Regulatory press release9/4/2025, 10:31 AM

ALK expands the Executive Leadership Team to include key commercial regions

Regulatory press release8/21/2025, 5:30 AM

Six-month interim report (Q2) 2025 (unaudited)

Press release8/14/2025, 12:56 PM

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025

Regulatory press release8/12/2025, 12:45 PM

ALK upgrades its full-year revenue outlook

Press release7/21/2025, 10:25 AM

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system

Regulatory press release7/18/2025, 12:01 PM

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK

Press release6/26/2025, 7:17 AM

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

Press release6/16/2025, 12:03 PM

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

Press release6/4/2025, 2:48 PM

ALK participates at Jefferies Global Healthcare Conference 2025 in New York

Press release5/8/2025, 2:27 PM

ITULATEK® approved for treatment of children and adolescents in Canada

Regulatory press release5/6/2025, 5:30 AM

Three-month interim report (Q1) 2025 (unaudited)

Regulatory press release5/2/2025, 11:59 AM

ALK enters into neffy® co-promotion agreement in the USA

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.